📰 Treatment Data News
Page 2 - Treatment Data News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Treatment Data. Real-time updates on events, politics, business and more.
June 13, 2022
The number of cases of people seeking treatment for problem cocaine use has tripled between 2015-2021…
June 13, 2022
The number of cases of people seeking treatment for problem cocaine use has tripled between 2015-2021…
May 26, 2022
/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and...
May 26, 2022
/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and...
March 19, 2022
Ann Murphy reports on how cocaine has moved from being a problem that was largely confined to more urban areas to become an increasing scourge in towns and villages across the country.
April 29, 2021
Santhera and ReveraGen Announce New 2.5-year Treatment Data with Vamorolone in Duchenne Muscular Dystrophy Pratteln, Switzerland, April 28, 2021 – Santhera Pharmaceuticals (SIX: SANN) and ReveraGen Biopharma announce new clinical data of 2.5-year treatment outcome with vamorolone in patients with Duchenne muscular dystrophy (DMD). These Phase 2a long-term treatment data demonstrate a maintenance of treatment effect, equivalent to a delay of about two years in decline for time to stand (TTST...
April 28, 2021
Santhera and ReveraGen Announce New 2.5-year Treatment Data with Vamorolone in Duchenne Muscular Dystrophy Pratteln, Switzerland, April 28, 2021 – Santhera Pharmaceuticals (SIX: SANN) and ReveraGen Biopharma announce new clinical data of 2.5-year treatment outcome with vamorolone in patients with Duchenne muscular dystrophy (DMD). These Phase 2a long-term treatment data demonstrate a maintenance of treatment effect, equivalent to a delay of about two years in decline for time to stand (TTST...